Received Mar 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
Neck pain; lower back pain; This non-serious case was reported by a consumer via call center representative and described the occurrence of neck pain in a 69-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (1st dose on unknown date). Concurrent medical conditions included chemotherapy, diabetes, seizure, memory deficit, stomach pain and cholesterol. Concomitant products included brigatinib (Alunbrig), vitamin d, insulin lispro (Humalog), insulin glargine (Lantus), levetiracetam, memantine hydrochloride (Memantine), aluminium hydroxide gel, dried, magnesium carbonate (Pepcid) and rosuvastatin calcium (Rosuvastatin). On 03-MAR-2025, the patient received the 2nd dose of Shingrix. On 04-MAR-2025, 1 days after receiving Shingrix, the patient experienced neck pain (Verbatim: Neck pain) and low back pain (Verbatim: lower back pain). The outcome of the neck pain and low back pain were not resolved. It was unknown if the reporter considered the neck pain and low back pain to be related to Shingrix. It was unknown if the company considered the neck pain and low back pain to be related to Shingrix. Additional Information: GSK receipt date: 11-MAR-2025 Patient reported neck and lower back pain after receiving the second dose of Shingrix.
Chemotherapy; Cholesterol; Diabetes; Memory deficit; Seizure; Stomach pain
Alunbrig; Vitamin d; Humalog; Lantus; Levetiracetam; MEMANTINE; Pepcid; ROSUVASTATIN